A Phase I, First-In-Human, Multiple Phase, Single and Multiple-Ascending Dose Study of TERN-201 in Healthy Human Participants
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2020
Price : $35 *
At a glance
- Drugs TERN 201 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors Terns Pharmaceuticals
- 10 Jan 2020 According to a Terns Pharmaceuticals media release, data from the study has been presented at the NASH-TAG Conference 2020.
- 10 Jan 2020 Results presented in a Terns Pharmaceuticals media release.
- 13 Aug 2019 According to a Terns Pharmaceuticals media release, based on the interim results, the study has progressed to the multiple-dose phase.